> VPHM – It just occurred to me that the ribavirin interference issue could explain VPHM's assertion that a non-nuke polymerase inhibitor would be preferable.<
Plausible on its face, but VPHM has not offered this answer when asked. Hence, this is not the reason for their assertion about drug classes unless they were being coy by trying to conceal the fact that they got wind of the ACAAC paper.
Market Data 
Markets 
AI
